Identifying common prognostic factors in genomic cancer studies: A novel index for censored outcomes by Rouam, Sigrid et al.
Rouam et al. BMC Bioinformatics 2010, 11:150
http://www.biomedcentral.com/1471-2105/11/150
Open Access RESEARCH ARTICLE
© 2010 Rouam et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
Research article Identifying common prognostic factors in genomic 
cancer studies: A novel index for censored 
outcomes
Sigrid Rouam*1,2, Thierry Moreau3 and Philippe Broët1,2
Abstract
Background: With the growing number of public repositories for high-throughput genomic data, it is of great interest 
to combine the results produced by independent research groups. Such a combination allows the identification of 
common genomic factors across multiple cancer types and provides new insights into the disease process. In the 
framework of the proportional hazards model, classical procedures, which consist of ranking genes according to the 
estimated hazard ratio or the p-value obtained from a test statistic of no association between survival and gene 
expression level, are not suitable for gene selection across multiple genomic datasets with different sample sizes. We 
propose a novel index for identifying genes with a common effect across heterogeneous genomic studies designed to 
remain stable whatever the sample size and which has a straightforward interpretation in terms of the percentage of 
separability between patients according to their survival times and gene expression measurements.
Results: The simulations results show that the proposed index is not substantially affected by the sample size of the 
study and the censoring. They also show that its separability performance is higher than indices of predictive accuracy 
relying on the likelihood function. A simulated example illustrates the good operating characteristics of our index. In 
addition, we demonstrate that it is linked to the score statistic and possesses a biologically relevant interpretation.
The practical use of the index is illustrated for identifying genes with common effects across eight independent
genomic cancer studies of different sample sizes. The meta-selection allows the identification of four genes (ESPL1,
KIF4A, HJURP, LRIG1) that are biologically relevant to the carcinogenesis process and have a prognostic impact on
survival outcome across various solid tumors.
Conclusion: The proposed index is a promising tool for identifying factors having a prognostic impact across a 
collection of heterogeneous genomic datasets of various sizes.
Background
In clinical cancer research, recent advances in genome-wide
technologies have enabled researchers to identify large-
scale genomic changes having a potential prognostic impact
on time-to-event outcomes. The growing number of public
repositories for high-throughput genomic data facilitates
the retrieval and combination of various datasets produced
by independent research groups (for a few: GEO  [1],
Oncomine [2], ArrayExpress [3]). These databases poten-
tially represent valuable resources for identifying genomic
factors that have a common prognostic impact on clinical
outcomes (e.g. time to local or distant recurrence) across
multiple cancer types. However, the joint analysis of these
heterogeneous datasets is difficult due to the fact that they
are usually of varying sample size, investigate different sur-
vival outcomes or are related to different tumors entities. In
this context, defining a procedure for identifying common
genomic risk factors across multiple heterogeneous datasets
is a promising but very challenging task. In recent years,
several authors [4-7] have proposed meta-profiling methods
for class comparison, designed to identify common tran-
scriptional features of the tumoral process (normal versus
tumor state).
In the framework of the widely used Cox model [8] for
analyzing possibly censored time-to-event or survival data,
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different procedures for feature selection across multiple
gene expression datasets can be defined. Basically, each
gene expression measurement is included in a simple Cox
model, giving rise to an estimation of the corresponding
hazard ratio and to a statistic for testing the null hypothesis
of no association between survival outcome and gene
expression changes. Simple procedures, frequently used in
practice, consist of ranking the genes in each dataset from
the highest (or lowest) value to the lowest (or highest) value
according to either the estimated hazard ratio or quantities
derived from the test statistic (e.g. p-value), and finally to
select those that appear at the intersection of the lists using
a defined thresholding procedure [9]. However, these
approaches suffer serious drawbacks that are mostly related
to the chosen selection criteria. Choosing the estimated haz-
ard ratio clearly ignores the variability of the data, while the
choice of quantities derived from test statistics leads to
emphasize large datasets, since it is well known that every
test statistic increases with the sample size.
In meta-selection of heterogeneous genomic datasets, tak-
ing into account both the magnitude of the prognostic
impact of factors and the variability of the data without
being highly dependent on the sample size is likely to be
more biologically relevant. Addressing this issue led us to
propose a novel index designed for genomic survival analy-
sis that provides information about the capability of a
genomic factor to separate patients according to their time-
to-event outcome. Our work shares conceptual links with
the framework of predictive ability measures that aim to
determine which covariates have the greatest explanatory
interest. For censored data, two main frameworks have
been proposed for quantifying the predictive ability of a
variable to separate patients: (i) concordance, which quanti-
fies the degree of agreement among the ranking of observed
failure times according to the explained variables and is
used to assess the discriminatory performance of a model
[10,11]; (ii) proportion of explained variation, which quan-
tifies the relative gain in prediction ability between a cova-
riate-based model and a null model (without explained
variables) by analogy with the well-known linear model. In
this latter case, two approaches have been considered. The
first one focuses on comparing empirical survival functions
with and without covariates [12-15]. The second one con-
siders statistical quantities which are directly or indirectly
related to the likelihood function [16-19]. In this paper, we
propose a novel index that is linked to the approach dis-
cussed above. It is related to the score statistic and well-
suited for meta-selection of genomic datasets. Our index is
interpreted as the ability of a gene to separate patients
observed to experience the event of interest from those who
do not experience the event among the risk set at every
observed failure time. As shown in this study, increasing
values of the index correspond to a higher effect due to the
gene variable. In contrast to a test statistic, our index is not
highly sensitive to sample size variation which makes it
well-suited for meta-selection from datasets with various
sample sizes.
We report and discuss the statistical properties of the
index obtained from simulation experiments, and compare
it to Allison's index [16] and its modified version [18],
Nagelkerke [17] and Xu and O'Quigley's [19] indices. In
addition, the properties of these indices are illustrated on a
fictitious example, where data are simulated so as to mimic
a real study combining datasets of different sample sizes.
We then illustrate the capability of the index for combining
the results of eight cancer studies of different sample sizes
and with different outcomes.
Results
Statistical properties of the proposed index and 
comparison with classical indices
Simulation Scheme
A simulation study was performed to evaluate the behavior
of the proposed index, denoted   and compare it to Alli-
son's index [16], a modified version of Allison's index [18],
Nagelkerke [17] and Xu and O'Quigley's [19] indices
denoted   and   respectively (see the
Methods Section for the description of the five indices)
under proportional and non-proportional hazards regression
models, using different values of the regression parameter,
different covariate distributions and different sample sizes.
Scenarios with various independent censoring distributions
were also considered.
The simulation protocol was as follows. For each subject
i, i = 1,, n, we considered one covariate Z with either a
discrete (Bernoulli V(0.5)) or a continuous (uniform   [0,
]) distribution. These two distributions of Z  were
standardized to have the same variance. Survival times T
were generated with the survival function S(t; z) = exp(-
teβZ) (proportional hazards model) or S(t; z) = (1 + t · eβZ)-1
(proportional odds model). For these two survival distribu-
tions, the hazard ratios were HR = eβ for the proportional
hazard model and HR = [1 + (eβ - 1)S0(t)]-1 for the propor-
tional odds model, S0(t) refering to the baseline survivor
function. In our simulation scheme, eβ was set to 1 (null
effect), to small values; 1.25, 1.5, 1.75, medium values; 2,
3, and high values; 4, 5. The sample sizes n of the data were
taken equal to 50, 100, 500 and 1, 000.
The censoring mechanism was assumed to be indepen-
dent from T given Z and the distribution of the censoring
variable Ci, i = 1,, n was either uniform Ci ~ {0,  r} or
exponential Ci~ {γ }. The calculation of the parameters r
and γ as functions of the expected overall percentage of
censoring pc is described in Additional file 1. The percent-
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age of censoring was taken equal to 0%, 25% and 50%. For
each configuration 1,000 repetitions were generated.
Simulation Results
The table in Additional file 2 displays the results of the sim-
ulations for   for four different sample sizes and two dif-
ferent covariate distributions, considering a Cox
proportional hazards model. As seen from Additional file 2,
when β = 0, i.e. in the absence of covariates, our index
approaches 0 for n = 50 to 1, 000; the separability is close to
0. The index increases towards 1 with |β|, the separability
increases with the effect of the covariate. When β≠ 0, the
value of   for the different sample sizes is fairly stable,
in particular for moderate or high effects (eβ ≥ 1.5). The
mean values of our index for n = 50 to 500 are close to the
mean values obtained for n = 1, 000 which is assumed to
approach its asymptotic limit. The standard errors of 
(indicated in brackets in Additional file 2) are small even
when censored, and, as expected, decrease when n
increases. Our index is slightly sensitive to the censoring
rate, especially for high values of hazard ratio. Similar com-
ments can be made when dealing with an exponential cen-
soring mechanism (results not shown).
Figures 1, 2, 3 and 4 display, for a Cox model, the differ-
ences  δ  between the mean of   and the mean of
 and   respectively, for n = 100, for dif-
ferent percentage of censoring pc, different covariate distri-
butions and with a uniform censoring mechanism. The
means of the differences δ are always positive. They are
close to zero for small hazard ratios and increase with
higher hazard ratios. The differences between   and 
increase with the percentage of censoring, which is not sur-
prising since the Nagelkerke's index is known to be sensi-
tive to censoring [15]. The two indices   and   have
a similar behavior relatively to  . This is expected since
O'Quigley et al [18] propose to use   as a simple working
approximation of their index. The same results are obtained
for n = 50, 500 and 1, 000 and for an exponential censoring
mechanism (results not shown). For eβ ≥ 2, the 95% confi-
dence interval for the differences of the three graphs does
not comprise 0, thus in each case the difference δ is signifi-
cant. The table in Additional file 3 and Figures 5, 6, 7 and 8
display the results of the simulations under a proportional
odds model. The mean values of the different indices are
lower than in the case of a proportional hazards model. All
indices are more sensitive to censoring. Our index shows
higher mean values than the other indices, especially in
case of a Bernoulli distribution.
Evaluation of the index in meta-selection
Simulation Scheme
In this subsection, using a basic example we evaluated the
practical interest of our index   when combining the
information contained in two studies with different sample
sizes. The method used to generate the two datasets was
inspired by Bair and Tibshirani [20] but modified in order
to resemble the structure of real genomic data. The two
datasets mimicked the analysis of the prognosis impact of
transcriptional changes for a set of 1, 000 genes. The two
datasets were of unequal size and composed of n = 150 and
50 individuals, respectively. To each individual i, i = 1,, n;
n = 150 or 50, we associated a survival time Ti, a censoring
time Ci and vector of 1,000 quantitative values Zi = { ;
g = 1,, 1, 000} (e.g. expression measurement).
To perform a fair evaluation of our index, we simulated
survival data with either an exponential distribution given
by S(t) = exp(-teξ) (proportional hazard model) or a log-
logistic survival distribution given by S(t) = (1 + t · eξ)-1
(non-proportional hazard model). For individuals i such as
1 ≤ i ≤ n/2 (n = 150 or 50), the parameter ξ was equal to 0.
For individuals i such as n/2 + 1 ≤ i ≤ n (n = 150 or 50), eξ
was equal to 3 and 5. We defined individuals i = 1 to n/2 as
belonging to the group of patients with low risk of occur-
rence of the event of interest and individuals from i = n/2 +
1 to n to the group with high risk of occurrence of the event.
For each dataset, censoring times Ci (i = 1,, n; n = 150
or 50) were considered independent from survival times
and with a uniform distribution on {0, r}, r chosen in order
to have an expected percentage of censoring of 30%.
The observed time to follow-up   (i = 1,, n; n = 150
or 50) was equal to the minimum between the two previ-
ously defined times Ti and Ci.
For the two datasets, for each individual i, 1,000 gene
expression values   (i = 1,, n; n = 150 or 50; g = 1,,
1, 000) were generated, according to the simulation scheme
shown on the figure in Additional file 4. Gene expression
values from g = 1 to 50 for individuals i = 1 to n/2 (n = 150
or 50) followed a log-normal distribution Log- (μ = 4, σ
= 1.5) with   and
. For the rest of the individuals (i
= n/2 + 1,, n; n = 150 or 50), gene expression values fol-
lowed a distribution Log- (0, 1.5). Gene expression val-
ues from g = 51 to 100 for individuals i = 1 to n/2 (n = 150
or 50) followed a log-normal distribution with parameters μ
= 3 and σ = 1.5 Log- (3, 1.5). For the rest of the individ-
uals (i = n/2 + 1,, n; n = 150 or 50), gene expression val-
ues followed a distribution Log- (0, 1.5). For gene
D0
∗
D0
∗
D0
∗
D0
∗
ρρ NkN R
22 2 ,, ρ XOQ
2
D0
∗ RN
2
ρk
2 ρ XOQ
2
D0
∗
ρk
2
D0
∗
Zi
g ()
Ti
∗
Xi
g ()
N
EX e ()
. =
+ μσ 05
2
VX e e () ( ) =−
+ 2
22
1
μσ σ
N
N
NRouam et al. BMC Bioinformatics 2010, 11:150
http://www.biomedcentral.com/1471-2105/11/150
Page 4 of 19
expression values from g = 100 to 150 and for 40% individ-
uals randomly selected among the n (n = 150 or 50), the
 (i 8 N, g = 100,, 150) followed a log-normal distri-
bution Log- (1, 1.5), whereas for the remaining individu-
als, they followed a log-normal distribution Log- (0,
1.5). For gene expression values from g = 151 to 250 and
for 50% individuals randomly selected among the n, the
 (i 8 N; g = 151,, 250) followed a log-normal distri-
bution Log- (0.5, 1.5), whereas for the remaining indi-
viduals, they followed a log-normal distribution Log- (0,
1.5). For gene expression values from g = 251 to 350 and
for 70% individuals randomly selected among the n, the
Xi
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N
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g ()
N
N
Figure 1 Graphic of the differences δ between the mean values of   and the mean values of   as a function of the hazard ratio, for 
a Cox proportional hazards model. Mean of   as a function of the relative risk eβ, for different percentages of censoring pc, for a covariate 
with Bernoulli V(1/2) or uniform   [0,  ] distribution, n = 100 and a uniform censoring mechanism.
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 (i 8 N; g = 251,, 350) followed a log-normal distri-
bution Log-  (0.1, 1.5), whereas for the remaining indi-
viduals, they followed a log-normal distribution Log- (0,
1.5). Finally, for gene expression values from g = 351 to 1,
000, the   (i = 1,, n; g = 351,, 1, 000) followed a
log-normal distribution Log- (0, 1.5) for all individuals.
As genes involved in the same or related pathway are
likely to be coexpressed, we introduced correlations
between genes. To evaluate the behavior of our index in the
context of dependent data, we generated datasets with so-
called "clumpy" dependence (gene measurements are
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Figure 2 Graphic of the differences δ between the mean values of   and the mean values of   as a function of the hazard ratio, for a 
Cox proportional hazards model. Mean of   as a function of the relative risk eβ, for different percentages of censoring pc, for a covariate 
with Bernoulli V(1/2) or uniform   [0,  ] distribution, n = 100 and a uniform censoring mechanism.
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dependent in small groups, but each group is independent
from the others). We applied the following protocol [21,22].
For each group of ten genes indexed by l, l = 1,, 100, a
random vector A = ail, i = 1,, n, was generated from a
standard log-normal distribution Log- (0, 1). The data
matrix  Z  was then built so that
 with ρ equal to 0.25, 0.5
or 0.75. Finally and in order to show the behavior of our
index in situations close to real genomic data analysis, we
standardized the dataset using classical quantile normaliza-
tion [23].
In this simulation scheme, the first hundred genes were
differentially expressed between the low and high risk
N
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Figure 3 Graphic of the differences δ between the mean values of   and the mean values of   as a function of the hazard ratio, for 
a Cox proportional hazards model. Mean of   as a function of the relative risk eβ, for different percentages of censoring pc, for a covariate 
with Bernoulli V(1/2) or uniform   [0,  ] distribution, n = 100 and a uniform censoring mechanism.
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group of patients. The other 250 genes were not linked to
the low and high risk status, but were distributed differen-
tially according to a binary factor (with various means)
unlinked to the low/high risk status. The remaining genes
were not linked to the low and high risk status.
For a given threshold, we calculated the number of genes
common to the two simulated datasets with the five indices,
for the different survival distributions, the different hazards
ratio values and the different correlations between genes.
We estimated the true positive fraction (TPF, number of
true positives found divided by the number of truly prog-
nostic genes) and the true negative fraction (TNF, number
of true negatives divided by the number of truly non-prog-
nostic genes) obtained with the five indices,  , D0
∗
Figure 4 Graphic of the differences δ between the mean values of   and the mean values of  as a function of the hazard ratio, for 
a Cox proportional hazards model. Mean of   as a function of the relative risk eβ, for different percentages of censoring pc, for a cova-
riate with Bernoulli V(1/2) or uniform   [0,  ] distribution, n = 100 and a uniform censoring mechanism.
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 and   as a function of the threshold target
value. These criteria were estimated by the mean over one
hundred iterations of: (i) the proportion of correct selection
(i.e. when the selected genes g belonged to {0,, 100})
among the modified genes; (ii) the proportion of correct
'non-selection' (i.e. when the selected genes g belonged to
{101,, 1, 000}) among the non-modified genes, respec-
tively.
Considering this procedure, the most successful criterion
was the one that achieve the best operating characteristics.
Simulation Results
Figure 9 displays the true positive fraction versus the false
negative fraction (number of false positives found divided
by the number of truly non-prognostic genes) for four con-
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Figure 5 Graphic of the differences δ between the mean values of   and the mean values of   as a function of the odds ratio, for a 
proportional odds model. Mean of   as a function of the odds ratio eβ, for different percentages of censoring pc, for a covariate with Ber-
noulli V(1/2) or uniform   [0,  ] distribution, n = 100 and a uniform censoring mechanism.
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figurations: ρ = 0.5, eξ = 3 and 5 and for a proportional and
non-proportional model. For the five indices, higher operat-
ing characteristics are obtained under a proportional haz-
ards model (Figure 9.a and 9.b) as compared to a
proportional odds model (Fig 9.c and 9.d). Moreover, for a
given distribution and a given threshold, our index gives the
best results with higher true positive and true negative frac-
tions. Results for the four other indices are very close to
each other. Results with other levels of correlation (ρ = 0.25
and 0.75) are very close to those obtained with ρ = 0.5
(curves not shown here).
Application of the index on real data
Datasets
In this section, we exemplify the use of the proposed index
by identifying transcriptomic prognostic factors common to
Figure 6 Graphic of the differences δ between the mean values of  and the mean values of   as a function of the odds ratio, for a 
proportional odds model. Mean of   as a function of the odds ratio eβ, for different percentages of censoring pc, for a covariate with Ber-
noulli V(1/2) or uniform   [0,  ] distribution, n = 100 and a uniform censoring mechanism.
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eight studies corresponding to five different solid tumors
such as breast, lung, bladder cancer, glioma and melanoma.
We compared our index to the four indices and two classi-
cal test-based criteria (q-values derived from the log-likeli-
hood ratio and robust score statistics). The data consisted of
eight independent genomic studies [24-31], with different
survival outcomes and different sample sizes which sam-
ples were hybridized on a same platform (Affymetrix
HU133 Plus 2.0 or HU133A ; Affymetrix, Santa Clara, CA,
USA). The datasets are publicly available on the GEO site
under the labels GSE2034, GSE1456, GSE11121,
GSE4573, GSE5287, GSE4271, GSE4412 and GSE19234,
respectively, and they are briefly described below.
GSE2034 cohort, breast cancer [24] This series includes
286 lymph-node negative patients, among which 106 have
developed a metastasis which is the event of interest in this
Figure 7 Graphic of the differences δ between the mean values of   and the mean values of   as a function of the odds ratio, for a 
proportional odds model. Mean of   as a function of the odds ratio eβ, for different percentages of censoring pc, for a covariate with Ber-
noulli V(1/2) or uniform   [0,  ] distribution, n = 100 and a uniform censoring mechanism.
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study. Metastasis-free survival was defined as the time
interval from treatment until the apparition of distant
relapse or last follow-up. The median metastasis-free sur-
vival time was 80 months. The two years metastasis-free
survival was 83.9% [79.8%; 88.3%], and the five years
metastasis-free survival was 66.7% [61.4%; 72.4%].
GSE1456 cohort, breast cancer [25] This series com-
prises 159 primary breast cancer patients (referred as Stock-
holm cohort). Metastasis-free survival measured the time
from initial therapy until the first metastasis or last follow-
up. The median metastasis-free survival time was 80
months. The two years metastasis-free survival was 87.9%
Figure 8 Graphic of the differences δ between the mean values of   and the mean values of   as a function of the odds ratio, for 
a proportional odds model. Mean of   as a function of the odds ratio eβ, for different percentages of censoring pc, for a covariate with 
Bernoulli V(1/2) or uniform   [0,  ] distribution, n = 100 and a uniform censoring mechanism.
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[83.0%, 93.2%], and the five years metastasis-free survival
was 77.6% [71.3%, 84.4%].
GSE11121 cohort, breast cancer [26] This series is com-
posed of 200 lymph node-negative breast cancer patients
who were not treated by systemic therapy after surgery.
Metastasis-free survival was defined as the interval from
the date of therapy to the date of diagnosis of metastasis or
last follow-up. The median metastasis-free survival time
was 149 months. The two years metastasis-free survival
was 92.9% [89.3%; 96.5%], and the five years metastasis-
free survival was 85.4% [80.6%; 90.6%].
GSE4573 cohort, lung cancer [27] This series comprises
129 patients with different stages of squamous cell carcino-
mas, who underwent surgery resection of the lung. Overall
survival was defined as the time from surgery until death or
last follow-up. The median overall survival time was 63
months. The two years overall survival was 70.5% [63.1%;
78.9%], and the five years overall survival was 56.8%
[48.3%; 66.7%].
Figure 9 Operating characteristics of  ,   and  . Graphic of the true positive fraction versus the true negative fraction cal-
culated for the five indices with different thresholds. Fig 9.a and 9.b display the results for a proportional hazard model, for eξ = 3 and 5 respectively ; 
Fig 9.c and 9.d display the results for a proportional odds model, for eξ = 3 and 5, respectively.
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GSE5287 cohort, bladder cancer [28] This series is com-
posed of 30 patients who received chemotherapy. Overall
survival was defined as the time from first chemotherapy to
death or last follow-up. The median overall survival time
was 47 months. The two years overall survival was 96.7%
[90.5%; 100%], and the five years overall survival was
46.7% [31.8%; 68.4%].
GSE4271 cohort, glioma [29] This study comprises 77
patients with high-grade gliomas who underwent surgery
(resection) of the brain. The overall survival was measured
from initial surgical resection to death or last follow-up.
The median overall-survival was 21 months. The two years
overall-survival was 45.5% [35.6%, 58.1%], and the five
years overall-survival was 22.6% [14.7%, 34.9%].
GSE4412 cohort, glioma [30] This series includes 85
patients who suffered of glioma of grade III or IV of any
histologic type. The overall survival corresponded to the
time from inclusion for surgical treatment to death or last
follow-up. The median overall-survival was 13 months.
The two years overall-survival was 33.2% [24.3%, 45.3%],
and the five years overall-survival was 22.1% [12.9%,
37.7%].
GSE19234 cohort, melanoma [31] The authors consid-
ered 44 metastatic melanoma tissue samples. Overall sur-
vival was referred as the time from excision of the
metastatic lesion to death or last follow-up. The median
overall-survival was 46 months. The two years overall-sur-
vival was 76.7% [65.0%, 90.4%], and the five years over-
all-survival was 56.5% [43.1%, 74%].
For these studies, the hybridizations were performed on
the Affymetrix GeneChip HU133A, except for the mela-
noma cohort where they were performed on HU133 Plus
2.0 (HU133A+HU133B). For each patient, we considered
the information obtained from 22,283 transcripts
(HU133A).
For selecting a threshold target value, we considered the
intersection procedure introduced by Blangiardo and Rich-
ardson [32]. The main steps of this procedure were as fol-
lows. We first ranked the genes according to a measure of
interest on probability scale (e.g. the p-value or the q-
value). For each experiment and for a given threshold, we
counted the number of differentially expressed genes in
common between the different experiments. This number
was then compared to the expected number of genes in
common, calculated under the hypothesis of independence
between the experiments. The ratio between these two
numbers was calculated for all possible thresholds. Finally,
the threshold considered in the intersection selection proce-
dure was such as the ratio was superior to 2 with a clinically
relevant survival difference. Here, we used this procedure,
with the following criteria: (1) our index  ; (2) Allison's
index  ; (3) the modified version of Allison's index  ;
(4) Nagelkerke's index  ; (5) Xu and O'Quigley's index
; (6) the q-value associated to the FDR (False Dis-
covery Rate) calculated on the robust score statistic and
estimated according to a non-parametric method [21]; (7)
the q-value associated to the FDR calculated on the log-
likelihood ratio statistic, estimated with the same method.
Selection of the Variables
The proposed index was calculated for the 22,283 gene
expression measures for the eight datasets. The intersection
procedure [32] led to a threshold equal of 0.07 for  .
For   ≥ 0.07 (which corresponds from our simulations
to a hazard ratio value around 1.5), we selected 5 transcripts
related to four genes (Table 1).
We identified HJURP and LRIG1 genes that are directly
involved in tumorigenesis. HJURP encodes an indispens-
able factor for chromosomal stability in immortalized can-
cer cells. It is up-regulated in lung cancer [33]. LRIG1
encodes a protein that acts as a growth suppressor in breast
cancer [34]. Its expression decreases in human breast can-
cer and the majority of ErbB2+ breast tumors show under-
expression of LRIG1. In our series, the increase of HJURP
and decrease of LRIG1  gene expressions are associated
with a worse prognosis.
Our selection process also brought two genes involved in
cell cycle regulation. Gene KIF4A encodes a protein critical
for mitotic regulation including chromosome condensation,
spindle organization and cytokinesis. It possesses a func-
tional and physical link with the gene product of BRCA2
(breast cancer 2, early onset) [35]. Gene ESPL1 plays a cen-
tral role in chromosome segregation at the onset of ana-
phase. Its over-expression induces aneuploidy and
tumorigenesis [36]. The article of Zhang et al [36] showed
that the ESPL1 transcript is over-expressed in human breast
tumors. It is worth noting that ESPL1  and  KIF4A, have
been previously discussed in a meta-analysis conducted by
Carter  et al [37]. For these two genes, over-expression,
leading to a cell proliferation, is associated with a worse
prognosis.
Finally, for each gene from our selection, the hazard
ratios were in the same direction in each of the eight stud-
ies.
With a same threshold of 0.07, Allison's index 
selected 3 transcripts corresponding to genes KIF4A and
ESPL1  and Xu and O'Quigley's index   selected 2
transcripts corresponding to gene ESPL1. The transcripts
identified with these two indices are all included in our
selected subset. For   and   with a threshold of 0.07,
no transcript was selected. No transcript was selected rely-
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ing on the q-value calculated with the robust score or the
log-likelihood ratio statistics with a threshold of 0.40.
Discussion
Combining heterogeneous genomic datasets to select rele-
vant genomic factors having a common prognostic impact
across various tumor entities raises some concerns regard-
ing the choice of the statistic to be considered. In particular,
the use of hypothesis testing criteria across different data-
sets, such as p-values or related criteria, does not seem con-
venient due to its sensitivity to sample size. In this paper,
we propose a novel index that is well suited for a combined
analysis of heterogeneous genomic datasets and which
allows a selection of features with a similar prognostic
impact on outcome across studies.
The index possesses the four following properties: (1) it
has a straightforward and meaningful interpretation in
terms of percentage of separability between patients
observed to experience the event of interest and those
observed not to experience the event, according to their
gene expression levels. (2) It increases with the ability to
separate patients according to the gene variable from 0 to 1.
(3) The index is not highly dependent on the sample size.
(4) It is linked to the robust score statistic derived from the
partial log-likelihood which has a known asymptotic distri-
bution, and multiple testing criteria (e.g. FDR) can easily be
calculated.
Our index shares a common framework with Allison's
index, its modified version, Nagelkerke and Xu and
O'Quigley's indices. Indeed, these latter indices are closely
related to likelihood ratio statistics whereas ours relies on
the score statistic. Moreover, our index is directly inter-
preted in terms of separability, whereas the other indices
lack intuitive interpretation.
Simulation studies show that the separability perfor-
mance of our index are better than for Allison's index, its
modified version, Nagelkerke and Xu and O'Quigley's indi-
ces. In our simulated example, we illustrate the good oper-
ating characteristics of our index as compared to the
classical ones. However, more extensive simulations work
would be necessary to evaluate its performance in various
real-world scenarios.
In this work, a meta-selection performed from different
solid tumors allows the identification of a small set of genes
(ESPL1, KIF4A, HJURP, LRIG1) that are biologically rele-
vant to the carcinogenesis process and show a similar abil-
ity to separate patients according to time-to-event
outcomes. It would be worth conducting further studies to
validate or invalidate the prognostic impact of these genes.
It is important to note that for the analysis of these data we
have considered a very stringent method, which relies on
finding the intersection set across the different studies. If
necessary, less restrictive methods can be adopted. We have
to highlight that our index was primarily designed for a pro-
portional hazard model, but, as seen from our simulations,
it performs well in other contexts such as proportional odds
models. This last model corresponds to frequently encoun-
tered situations where the patient population becomes more
and more homogeneous as time goes on and the prognostic
effect decreases with time and disappears eventually. Future
studies are needed to investigate other non-proportional
hazard situations.
Table 1: Top survival related genes across the eight studies, for   ≥ 0.07.
AffyID Gene symbol UniGene Name Cytoband value of HR
211596-s-at LRIG1 leucine-rich repeats 
and immunoglobulin-
like domains 1
3p14 < 1
218355-at KIF4A kinesin family member 
4A
Xq13.1 > 1
218726-at HJURP Holliday junction 
recognition protein
2q37.1 > 1
204817-at ESPL1 extra spindle pole 
bodies homolog 1 (S. 
cerevisiae)
12q13.13 > 1
38158-at ESPL1 extra spindle pole 
bodies homolog 1 (S. 
cerevisiae)
12q13.13 > 1
AffyID, Affymetrix identification code for each probe set ; HR, hazard ratio
If HR > 1, the over-expression of the gene is associated with a worse prognosis. If HR < 1, the over-expression of the gene is associated with a 
better prognosis.
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Finally, the proposed index may be appealing for time-to-
event data in other medical fields such as auto-immune and
infectious diseases in which identifying prognostic factors
among different entities is a promising challenge.
Conclusion
In conclusion, we propose a novel index for identifying fac-
tors having a prognostic impact across collection of hetero-
geneous datasets that relies on the concept of separability
and is not substantially affected by the sample size of the
study. As the number of public available datasets obtained
from independent studies keeps growing, our index is a
promising tool which can help researchers to select a list of
features of interest for further biological investigations.
Methods
Notations
Let   denote the value of a covariate Z for the ith subject
(i = 1,, n) associated to the gth gene (g = 1,, G). For each
patient i, let the random variables Ti and Ci be the survival
and censoring times, which are assumed to satisfy the clas-
sical condition of independent censoring [38]. In practice,
we observe   = min(Ti, Ci). Here we consider the possi-
bility of the presence of ties among the uncensored failure
times and we assume that there are N distinct times (of fail-
ure or censoring) and k distinct failure times (k ≤ N ≤ n).
For j = 1,, N, let D(tj) be the set of individuals failing at
time tj, R(tj) the risk set at tj and E(tj) the set of individuals
failing or censored at tj. We denote dj, nj and ej the cardinals
of these three sets, respectively. We also define R*(tj) as the
risk set without the subjects failing at tj and R*(tl(-j)) (for tl
<tj) as the risk set at time tl without the subjects failing or
censored at tj. Let   be the indicator of at least
one death at tj (where 1 is the indicator function).
The hazard function at time t for gene g can be written in
a semi-parametric proportional hazards form as [8]
where   (t) is an unknown baseline hazard function,
and β(g) is the regression parameter to be estimated. In the
presence of ties, the partial log-likelihood of the Cox model
[39] can be approximated according to the Peto and
Breslow method [40,41]
The first derivative of the partial log-likelihood, or score,
is:
In the following, the exponent (g) is omitted in order to
facilitate the reading. Consequently, β will refer to β(g), Zi,
to  , ? to ?(g)and Uj to .
Proposed index
The proposed index is based on the interpretative property
of the score deduced from the partial log-likelihood under
the Cox model as recalled above. At each time t = tj, j =
1,, N, we consider the quantities Uj calculated under the
null hypothesis (for β = 0) from the approximated Breslow
partial log-likelihood
From this latter expression, it appears that, for a given
covariate  Z, and at each event time tj, the Uj  can be
expressed as differences between the means of the covari-
ates of the group D(tj) of patients observed to experience
the event of interest, and the group R*(tj) of those observed
to not experience the event. The Uj provide a measure of
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separability between the two groups of patients D(tj) and
R*(tj) at time tj. Differences close to zero indicate a weak or
null separability; large differences indicate that the two
groups are well separated.
Hence, a global statistic over time can be computed as the
sum of these differences:  . The statistic Δ0 is
large if the two groups are well separated over time or for a
few time points with large values but with the same direc-
tional effect (proportional hazard assumption).
For distributional reasons which will appear later, instead
of the Uj, j = 1,, N, we use closely related quantities Wj
derived from the paper by Lin and Wei [42]. In the presence
of ties, we propose the following formula for Wj
The term   is a weighted average of the score calcu-
lated at times tl prior to time tj (tl <tj). The sum of the so-
called "robust" Wj, j = 1,, N is identical to the sum of the
Uj, but, as shown by Lin and Wei, the Wj are independent
and identically distributed, while the Uj are not. Simple cal-
culations show that the Wj can be rearranged as in the fol-
lowing expression:
with
The usual global robust score is computed as the sum of
the differences Wj, j = 1,, N (which is also equal to the
sum of the Uj). So, Δ0 can be re-expressed as the sum of the
Wj:
In Additional file 5, we show that
 ranges from 0 (null sepa-
rability under the proportional hazard model) to
 (maximal separability). The value Dmax
is a theoretical maximum of D0, which corresponds to the
case where β tends to infinity.
Finally,
gives a meaningful index that can be interpreted as the
percentage of separability over time between the event/non-
event groups. It is equal to 0 in the absence of separability
and increases toward 1 as the separability rises. To a factor
k, the index can also be interpreted as the robust score sta-
tistic (S0 = k ·  ) [43], whose distribution under the null
hypothesis is an asymptotic chi-square distribution with 1
degree of freedom. Multiple error criteria can thus be com-
puted using a parametric or non-parametric approach.
Existing indices
Several indices of predictive accuracy have been proposed
in the literature. Here, only indices with direct or indirect
links to the likelihood ratio function and with a known dis-
tribution after transformation under the null hypothesis are
considered.
The indices are the following: (i) Allison's index
[16], based on a transformation of the partial log-likeli-
hood ratio test; (ii) a modified version of Allison's index
 proposed by O'Quigley et al [18]; (iii) Nagelkerke's
index  [17], which is a modification of Allison's index
dividing it by its maximum value, and (iv) Xu and O'Quig-
ley's index  [19] based on a transformation of the
Kullback-Leibler distance between the null and the alterna-
tive models.
The expressions of these four indices for one given gene
g; g = 1,, G are reminded here:
(i) Allison's index:
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(ii) Modified version of Allison's index:
In this version of the index, the log-likelihood ratio is
divided by the number of failures k. As discussed by
O'Quigley et al [18], the original version is more sensitive
to censorship than the modified one. In particular, O'Quig-
ley et al show that   approaches 0 as the percentage of
censored observation approaches 100%.
(iii) Nagelkerke's index:
with
This index was initially proposed to fully exploit the
range [0, 1], which is not the case with the original version
of Allison's index.
(iv) Xu and O'Quigley's index:
with
where   and   is the Kaplan-Meier
estimator of the distribution function of T.
The term   is derived from twice the Kullback-
Leibler distance between the null model (β = 0) and the
model taking the covariates into account (β ≠ 0).
The conditional probability   that the individual
indexed by i is selected for failure at the time tj is given by
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Additional file 1 Calculation of the parameters of the different cen-
soring mechanisms. We explain the procedure adopted for the calculation 
of the parameters of uniform and exponential censoring mechanisms as 
functions of the distribution of the covariates and the percentage of cen-
soring.
Additional file 2 Mean values of   in the framework of a Cox pro-
portional hazards model, for different relative risks eβ, different per-
centages of censoring pc and different sample sizes n, calculated for a 
covariate with Bernoulli V(1/2) or a uniform   [0,  ] distribu-
tion, for a uniform censoring mechanism (1,000 repetitions). The stan-
dard errors are indicated in brackets. Table with the mean values of 
 in the framework of a Cox proportional hazards model for different 
configurations.
Additional file 3 Mean values of   in the framework of a propor-
tional odds model, for different odds ratios eβ, different percentages 
of censoring pc and different sample sizes n, calculated for a covariate 
with Bernoulli V(1/2) or a uniform   [0,  ] distribution, for a 
uniform censoring mechanism (1,000 repetitions). The standard errors 
are indicated in brackets. Table with the mean values of   in the frame-
work of a proportional odds model for different configurations.
Additional file 4 Representation of the simulated example. Simple 
representation of the simulation plan.
Additional file 5 Proof establishing that 
 ranges from 0 to 
. We show that 
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